The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC).
 
Andrew Johns
No Relationships to Disclose
 
Matthew T Campbell
Honoraria - Axdev; Curio Science; Exelixis; Seagen; Targeted Oncology
Consulting or Advisory Role - Exelixis
Research Funding - Apricity Health (Inst); Aravive (Inst); Exelixis (Inst); Janssen Oncology (Inst); Pfizer/EMD Serono (Inst); SeaGen (Inst)
Travel, Accommodations, Expenses - AVEO; Exelixis; SeaGen
 
Mamie Gao
No Relationships to Disclose
 
Zita Dubauskas Lim
No Relationships to Disclose
 
Emily Wang
No Relationships to Disclose
 
Andrew Warren Hahn
Honoraria - Medscape
Consulting or Advisory Role - Intellisphere; Janssen Scientific Affairs
Research Funding - Bayer
Travel, Accommodations, Expenses - Dava Oncology
 
Jianjun Gao
Consulting or Advisory Role - AstraZeneca; AstraZeneca; crispr therapeutics; Infinity Pharmaceuticals; Janssen; Pfizer; Seagen
Travel, Accommodations, Expenses - AstraZeneca
 
Amishi Yogesh Shah
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Exelixis; Pfizer/EMD Serono
Research Funding - 4D Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); EMD Serono (Inst)
 
Pavlos Msaouel
Honoraria - Exelixis; Mirati Therapeutics; Pfizer
Consulting or Advisory Role - Axiom Healthcare Strategies
Research Funding - Bristol-Myers Squibb (Inst); Gateway for Cancer Research (Inst); Mirati Therapeutics (Inst); Takeda (Inst)
 
Nizar M. Tannir
Stock and Other Ownership Interests - Amgen; Arcturus Therapeutics; Arcus Biosciences; BioCryst; Corvus Pharmaceuticals; First Trust Amex Biotech (FBT); Johnson & Johnson/Janssen; Merck; Nuvation Bio; Revolution Medicines; Spdr S&P Pharmaceuticals ETF; Surface Oncology; Vanguard Health Care; Xencor
Honoraria - AstraZeneca/Merck; Bristol-Myers Squibb; Eisai; Exelixis; Intellisphere; Merck Sharp & Dohme; Nektar; Neoleukin Therapeutics; Oncorena
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Merck Sharp & Dohme; Nektar; Oncorena
Research Funding - Arrowhead Pharmaceuticals (Inst); Bristol Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Nektar (Inst); Novartis (Inst)